Danske Bank A S Makes New Investment in West Pharmaceutical Services, Inc. $WST

Danske Bank A S purchased a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 32,429 shares of the medical instruments supplier’s stock, valued at approximately $11,642,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of Nova Scotia raised its position in shares of West Pharmaceutical Services by 337.8% during the first quarter. Bank of Nova Scotia now owns 65,323 shares of the medical instruments supplier’s stock worth $16,373,000 after purchasing an additional 50,402 shares during the period. Hsbc Holdings PLC grew its position in shares of West Pharmaceutical Services by 23.3% in the 4th quarter. Hsbc Holdings PLC now owns 146,872 shares of the medical instruments supplier’s stock valued at $40,425,000 after purchasing an additional 27,745 shares during the period. Renaissance Technologies LLC increased its stake in West Pharmaceutical Services by 100.2% during the 1st quarter. Renaissance Technologies LLC now owns 209,660 shares of the medical instruments supplier’s stock worth $52,549,000 after purchasing an additional 104,924 shares in the last quarter. Conestoga Capital Advisors LLC raised its holdings in West Pharmaceutical Services by 6.7% during the 1st quarter. Conestoga Capital Advisors LLC now owns 130,970 shares of the medical instruments supplier’s stock worth $32,826,000 after buying an additional 8,179 shares during the period. Finally, Comerica Bank raised its holdings in West Pharmaceutical Services by 31.8% during the 4th quarter. Comerica Bank now owns 56,693 shares of the medical instruments supplier’s stock worth $15,599,000 after buying an additional 13,680 shares during the period. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Down 0.2%

Shares of WST stock opened at $352.94 on Friday. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 1 year low of $223.83 and a 1 year high of $386.00. The firm’s fifty day moving average price is $348.61 and its two-hundred day moving average price is $299.75. The firm has a market capitalization of $24.84 billion, a P/E ratio of 45.19, a PEG ratio of 2.47 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. The company had revenue of $872.30 million during the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The company’s quarterly revenue was up 13.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, equities analysts predict that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were given a dividend of $0.22 per share. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.2%. West Pharmaceutical Services’s payout ratio is 11.27%.

Analysts Set New Price Targets

Several research firms have recently weighed in on WST. Zacks Research cut shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 12th. TD Cowen restated a “buy” rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. Stephens reaffirmed an “overweight” rating and issued a $360.00 price objective on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. Citigroup upped their target price on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, West Pharmaceutical Services presently has a consensus rating of “Moderate Buy” and a consensus target price of $368.08.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.